-
Rotigotine: From Receptor Biology to Translation
2026-09-15
A translational framework for using Rotigotine as more than a symptomatic dopaminergic tool: integrating receptor biology, exposure design, analytical stability, and multimodal Parkinson’s disease research endpoints.
-
Imeglimin and Mitochondrial Function in CTS Cells
2026-09-15
This 2025 study examined whether imeglimin could improve mitochondrial dysfunction in subsynovial connective tissue cells derived from patients with idiopathic carpal tunnel syndrome. Its multi-parameter design linked cellular performance, oxidative stress, mitochondrial structure, gene expression, and permeability-transition biology, providing a useful framework for mechanistic CTS research.
-
Surrogate BBB Model Corrects Lysosomal Trapping
2026-09-14
Hu and colleagues developed a high-throughput Transwell blood-brain barrier surrogate using LLC-PK1-MOCK and LLC-PK1-MDR1 cells, combining permeability, P-glycoprotein efflux, and recovery measurements. The study linked MDR1-derived permeability with unbound brain distribution and showed that bafilomycin A1 correction can improve interpretation of compounds affected by lysosomal trapping.
-
Skin Methylome Aging: Methods and Therapeutic Screening
2026-09-14
Boroni et al. developed a skin-specific DNA methylation age predictor using 508 human skin samples and 2,266 CpG sites. The algorithm captured donor age, cellular passage, skin disease status, and responses to senotherapeutic treatment, creating a molecular endpoint for studying skin aging and evaluating interventions.
-
Twin-Derived iPSCs for Schizophrenia Research
2026-09-13
This reference study generated and characterized two human iPSC lines from dizygotic twins discordant for schizophrenia, creating a paired resource for investigating disease-related genetic and cellular variation. The lines showed pluripotency, genomic stability, three-germ-layer differentiation potential, and identity confirmation, supporting their future use in neural disease modeling and organoid-based research.
-
Disulfiram Workflows for Precision Cancer Research
2026-09-12
Disulfiram supports complementary cancer research workflows, from ALDH2-linked synthetic lethality in APC-deficient colorectal models to copper-associated proteasome inhibition in breast cancer systems. This practical guide connects dosing, orthogonal readouts, model selection, and troubleshooting for more interpretable results.
-
(Z)-4-Hydroxytamoxifen in Relapse Research
2026-09-12
A translational strategy for using (Z)-4-Hydroxytamoxifen to interrogate estrogen receptor biology while interpreting proliferation-tracing models of breast cancer relapse.
-
Perphenazine: From D2 Antagonism to Host Defense
2026-09-11
Perphenazine is more than a conventional dopamine probe. Its phenothiazine receptor binding profile, mitochondrial effects, and emerging host-directed antibacterial activity create a translational framework for connecting neuropharmacology research with immunology while preserving rigorous controls around pleiotropy and cytotoxicity.
-
EZ Cap™ EGFP mRNA Workflow and QC Guide
2026-09-11
EZ Cap™ EGFP mRNA (SKU R1002) provides a Cap 1 EGFP reporter mRNA input for testing delivery and transient expression in research assays. It is appropriate for controlled method development, but the available dossier does not establish a universal dose, cell type, delivery reagent, readout window, or expected result.
-
PP 1: A Mechanistic Map of Src Signaling
2026-09-10
PP 1, a Src family tyrosine kinase inhibitor, can separate kinase-dependent phosphorylation from metabolic vulnerabilities in cancer and immune models. This article explains how to interpret Lck, Fyn, Lyn, RET, and EDI3-related experiments without conflating biochemical potency with disease-specific efficacy.
-
L. reuteri FN041 Reshapes Colitis Microbiota
2026-09-10
This mouse study identifies human milk-derived Limosilactobacillus reuteri FN041 as a potential modulator of DSS-induced colitis through coordinated changes in intestinal inflammation, barrier integrity, gut microbiota, and metabolites. Its main contribution is a multi-omics view of probiotic activity, while its findings remain preclinical and require validation in controlled mechanistic and clinical studies.
-
CX-4945 (Silmitasertib): A CK2 Assay Playbook
2026-09-09
CX-4945 (Silmitasertib) is a selective CK2 inhibitor for dissecting kinase-dependent signaling, apoptosis, and cell-cycle control. This assay-focused guide connects oncology evidence with the CK2–CIAV host-dependency study while clarifying translational limits.
-
Perphenazine: D2 Antagonist Research Workflows
2026-09-09
Perphenazine supports receptor pharmacology, mitochondrial stress, opioid tolerance suppression, and host-directed antibacterial assays in one adaptable research workflow. This guide separates established findings from practical optimization recommendations so teams can design more reproducible neuropharmacology and macrophage experiments.
-
Rotigotine hydrochloride: Applied Research Workflows
2026-09-08
Build more interpretable Parkinson’s disease and depression-model experiments with a dopamine D2/D3 receptor agonist designed for dose, route, and behavioral readout comparisons. This guide translates rotigotine pharmacology into practical cell-based, rodent, formulation, and troubleshooting workflows.
-
MK0787 vs. β-Lactam Antibiotics in Resistant Bacteria
2026-09-08
The 1982 study by Cullmann and colleagues benchmarked N-formimidoyl thienamycin (MK0787) against several newer β-lactam antibiotics across resistant gram-negative and gram-positive clinical isolates. Its main contribution was to combine broad-spectrum MIC comparisons with bactericidal and β-lactamase-related analyses, providing a useful historical framework for antibiotic resistance research and comparative antibacterial activity assays.